This Article Full Text Full Text (PDF) Supplemental material Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferreira, D. M. Articles by Oliveira, M. L. S. Search for Related Content PubMed PubMed Citation Articles by Ferreira, D. M. Articles by Oliveira, M. L. S.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, May 2009, p. 636-645, Vol. 16, No. 5
1071-412X/09/$08.00+0     doi:10.1128/CVI.00395-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Characterization of Protective Mucosal and Systemic Immune Responses Elicited by Pneumococcal Surface Protein PspA and PspC Nasal Vaccines against a Respiratory Pneumococcal Challenge in Mice ^,

D. M. Ferreira,¹ M. Darrieux,¹ D. A. Silva,¹ L. C. C. Leite,¹ J. M. C. Ferreira Jr.,² P. L. Ho,¹ E. N. Miyaji,^1* and M. L. S. Oliveira^1*

Centro de Biotecnologia,¹ Laboratório de Imunoquímica, Instituto Butantan, São Paulo, Brazil²

Received 29 October 2008/ Returned for modification 3 February 2009/ Accepted 27 February 2009

Pneumococcal surface protein A (PspA) and PspC are virulence factors that are involved in the adhesion of Streptococcus pneumoniae to epithelial cells and/or evasion from the immune system. Here, the immune responses induced by mucosal vaccines composed of both antigens as recombinant proteins or delivered by Lactobacillus casei were evaluated. None of the PspC vaccines protected mice against an invasive challenge with pneumococcal strain ATCC 6303. On the other hand, protection was observed for immunization with vaccines composed of PspA from clade 5 (PspA5 or L. casei expressing PspA5) through the intranasal route. The protective response was distinguished by a Th1 profile with high levels of immunoglobulin G2a production, efficient complement deposition, release of proinflammatory cytokines, and infiltration of neutrophils. Intranasal immunization with PspA5 elicited the highest level of protection, characterized by increased levels of secretion of interleukin-17 and gamma interferon by lung and spleen cells, respectively, and low levels of tumor necrosis factor alpha in the respiratory tract.

---

* Corresponding author. Mailing address: Centro de Biotecnologia, Instituto Butantan, Av. Vital Brasil 1500, 05503-900 São Paulo, Brazil. Phone: 55-11-3726-7222, ext. 2244. Fax: 55-11-3726-1505. E-mail for M. L. S. Oliveira: mloliveira{at}butantan.gov.br. E-mail for E. N. Miyaji: enmiyaji{at}butantan.gov.br

Published ahead of print on 11 March 2009.

Supplemental material for this article may be found at http://cvi.asm.org/.

---

Clinical and Vaccine Immunology, May 2009, p. 636-645, Vol. 16, No. 5
1071-412X/09/$08.00+0     doi:10.1128/CVI.00395-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Francis, J. P., Richmond, P. C., Pomat, W. S., Michael, A., Keno, H., Phuanukoonnon, S., Nelson, J. B., Whinnen, M., Heinrich, T., Smith, W.-A., Prescott, S. L., Holt, P. G., Siba, P. M., Lehmann, D., van den Biggelaar, A. H. J. (2009). Maternal Antibodies to Pneumolysin but Not to Pneumococcal Surface Protein A Delay Early Pneumococcal Carriage in High-Risk Papua New Guinean Infants. CVI 16: 1633-1638 [Abstract] [Full Text]